TOGA
Regimen
- Experimental
- trastuzumab + XP or FP chemotherapy
- Control
- XP or FP chemotherapy
Population
HER2-positive advanced gastric/GEJ cancer as first-line therapy
Key finding
mOS 13.8 vs 11.1 mo (HR 0.74, 95% CI 0.60-0.91, p=0.0046); IHC3+/FISH+ subset mOS 16.0 vs 11.8 mo (HR 0.65)
Source: PMID 20728210
Timeline
Guideline citations
- NCCN GASTRIC (p.45)
- CSCO GASTRIC 2025 (p.32)⚠️ OCR source